Literature DB >> 15866997

Tadalafil improved erectile function at twenty-four and thirty-six hours after dosing in men with erectile dysfunction: US trial.

Jay M Young1, Robert A Feldman, Stephen M Auerbach, Joel M Kaufman, Carmen S Garcia, Wei Shen, Aileen M Murphy, Charles M Beasley, Jayne A Hague, Sanjeev Ahuja.   

Abstract

In a previous study assessing tadalafil for the treatment of erectile dysfunction (ED), tadalafil 20 mg was shown to improve erectile function for up to 36 hours vs placebo. This study sought to demonstrate the effectiveness of both 10- and 20-mg tadalafil vs placebo at 2 prespecified assigned times of 24 and 36 hours postdosing. This double-blind, placebo-controlled, parallel-group study randomized 483 men with ED into 6 groups according to a combination of treatment (placebo, tadalafil 10 or 20 mg) and assigned time (24 or 36 hours) for intercourse attempts. Patients were stratified by baseline ED severity based on Erectile Function Domain scores. The study had 4 phases: a 4-week run-in (no ED medication taken); a 2- to 4-week equilibration (dosing as needed); a 4- to 6-week assessment; and a 6-month open-label extension. During the assessment phase, men took a total of 4 doses of study medication, each dose separated by more than or equal to 7 days. Efficacy was measured as the mean per-patient percentage of successful intercourse attempts (Sexual Encounter Profile Diary Question 3: SEP3) during the assessment phase. Men taking either 10- or 20-mg tadalafil had a significant increase in SEP3 from baseline scores vs placebo at both 24 hours (P = .038 and <.001 for 10 and 20 mg, respectively) and 36 hours (P < .001 for both doses) postdose. The mean per-patient percentages of successful intercourse attempts for the 24-hour time point were 41.8%, 55.8%, and 67.3% for placebo and tadalafil 10 and 20 mg, respectively; for the 36-hour time point, the mean per-patient percentages were 32.8%, 56.2%, and 61.9% for placebo and tadalafil 10 and 20 mg, respectively. The most common treatment-emergent adverse events were headache, back pain, dyspepsia, and nasopharyngitis. Both 10- and 20-mg tadalafil improved erectile function for up to 36 hours postdosing in men with ED of varied severity.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15866997     DOI: 10.2164/jandrol.04126

Source DB:  PubMed          Journal:  J Androl        ISSN: 0196-3635


  11 in total

Review 1.  cGMP-dependent protein kinases and cGMP phosphodiesterases in nitric oxide and cGMP action.

Authors:  Sharron H Francis; Jennifer L Busch; Jackie D Corbin; David Sibley
Journal:  Pharmacol Rev       Date:  2010-09       Impact factor: 25.468

Review 2.  Molecular mechanisms of detrusor and corporal myocyte contraction: identifying targets for pharmacotherapy of bladder and erectile dysfunction.

Authors:  George J Christ; Steve Hodges
Journal:  Br J Pharmacol       Date:  2006-02       Impact factor: 8.739

3.  Silencing MaxiK activity in corporal smooth muscle cells initiates compensatory mechanisms to maintain calcium homeostasis.

Authors:  Giulia Calenda; Sylvia Ottilie Suadicani; Rodolfo Iglesias; David Conover Spray; Arnold Melman; Kelvin Paul Davies
Journal:  J Sex Med       Date:  2011-01-26       Impact factor: 3.802

4.  Psychosocial outcomes after initial treatment of erectile dysfunction with tadalafil once daily, tadalafil on demand or sildenafil citrate on demand: results from a randomized, open-label study.

Authors:  K Hatzimouratidis; J Buvat; H Büttner; P A S Vendeira; I Moncada; M Boehmer; C Henneges; F G Boess
Journal:  Int J Impot Res       Date:  2014-05-01       Impact factor: 2.896

5.  Predictors of Erectile Function Normalization in Men With Erectile Dysfunction Treated With Placebo.

Authors:  John P Mulhall; Martin Carlsson; Vera Stecher; Li-Jung Tseng
Journal:  J Sex Med       Date:  2018-05-09       Impact factor: 3.802

6.  Modified intention to treat reporting in randomised controlled trials: systematic review.

Authors:  Iosief Abraha; Alessandro Montedori
Journal:  BMJ       Date:  2010-06-14

7.  An open-label, multicenter, randomized, crossover study comparing sildenafil citrate and tadalafil for treating erectile dysfunction in Chinese men naïve to phosphodiesterase 5 inhibitor therapy.

Authors:  Wen-Jun Bai; Hong-Jun Li; Yu-Tian Dai; Xue-You He; Yi-Ran Huang; Ji-Hong Liu; Sebastian Sorsaburu; Chen Ji; Jian-Jun Jin; Xiao-Feng Wang
Journal:  Asian J Androl       Date:  2015 Jan-Feb       Impact factor: 3.285

8.  A randomized clinical trial investigating treatment choice in Chinese men receiving sildenafil citrate and tadalafil for treating erectile dysfunction.

Authors:  Wen-Jun Bai; Hong-Jun Li; Jian-Jun Jin; Wen-Ping Xu; Sorsaburu Sebastian; Xiao-Feng Wang
Journal:  Asian J Androl       Date:  2017 Jul-Aug       Impact factor: 3.285

Review 9.  Toward a new 'EPOCH': optimising treatment outcomes with phosphodiesterase type 5 inhibitors for erectile dysfunction.

Authors:  R Sadovsky; G B Brock; S W Gutkin; S Sorsaburu
Journal:  Int J Clin Pract       Date:  2009-08       Impact factor: 2.503

10.  Fixed drug eruption caused by tadalafil--case report.

Authors:  Milan Bjekic; Milica Markovic; Sandra Sipetic
Journal:  An Bras Dermatol       Date:  2013 Jul-Aug       Impact factor: 1.896

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.